|Bid||0.7000 x 0|
|Ask||0.7100 x 0|
|Day's range||0.6700 - 0.7150|
|52-week range||0.5600 - 1.6100|
|Beta (5Y monthly)||2.91|
|PE ratio (TTM)||N/A|
|Earnings date||09 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||0.91|
Take, for instance, Aurora Cannabis (NASDAQ: ACB), a leader in the Canadian pot market, and Biogen (NASDAQ: BIIB), a notable biotech. Aurora Cannabis has consistently been one of the most talked-about stocks in the Canadian pot market since recreational adult use became legal some five years ago. Aurora Cannabis looks to be turning the corner, at least on the surface.
If you're a fan of investing in turnaround plays, Aurora Cannabis (NASDAQ: ACB) is a stock that you should probably know about. Aurora shareholders have had a (very) rough few years. Multiple factors are to blame, starting with its now-abandoned leave-no-customer-behind strategy, wherein it seriously overbuilt its cannabis production capacity as well as its retail footprint in an attempt to seize as much of the Canadian marijuana market as possible.
There just might be light at the end of the long, dark tunnel for this beleaguered cannabis company.